Navigation Links
Additional Efficacy Data from Satraplatin SPARC Phase 3,Investigational Trial Presented at Annual Meeting of American,Urological Association

the placebo arm. The hazard ratio was 0.64 (95% CI: 0.51-0.79, p<0.001), which translates into a 36% reduction in the relative risk of pain progression. These results were consistent across multiple pre-defined subsets of patients, including patients treated with prior Taxotere(R) (docetaxel). All pain progression events were assigned by a blinded independent review committee. Complementing the time to pain progression data, pain response rates were 24.2 percent for the satraplatin plus prednisone arm (N=351) compared with 13.8 percent for the placebo arm (N=181) (p=0.005). Pain response rates for patients treated with prior Taxotere were 25.7 percent for the satraplatin arm compared with 13.1 percent for control (p<0.015). All of the findings presented today continue to build on the data previously presented from the SPARC trial.

Pain response was assessed by patients using a weekly present pain intensity (PPI) and analgesic score. The PPI score was defined according to the McGill-Melzack questionnaire with 0 = no pain, 1 = mild pain, 2 = discomforting pain, 3 = distressing pain, 4 = horrible pain and 5 = excruciating pain. The criteria for pain response are a greater than or equal to 2 point reduction in the patients' weekly PPI score from baseline and maintenance of the two point reduction for at least five consecutive weeks in the setting of a stable or decreasing weekly analgesic score compared to baseline. Patients were evaluable for pain response if their baseline PPI score was greater than or equal to one and had completed four consecutive weekly assessments of PPI and analgesic scores during the study treatment.

Safety findings in the SPARC trial were consistent with previous clinical studies involving satraplatin. The most common adverse reactions consisted of myelosuppression (bone marrow functions): Twenty-one percent of patients in the satraplatin arm experienced grade 3 or 4 thrombocytopenia; 14 percent had leucopenia and 21 percent had n
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
2. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
3. Additional Data on CombinatoRx Drug Candidates CRx-102 and CRx-139 Presented at EULAR
4. Further Statistical Analysis of the Recent Phase III trial on Lead Product M6G Shows Additional Benefits
5. Novel Mechanism Insights and Additional Data on CombinatoRx Drug Candidates to Be Presented at Upcoming EULAR Meeting
6. Elixir Pharmaceuticals Presents Additional Preclinical Data Demonstrating the Potential of Ghrelin Antagonism to Regulate Metabolism, Body Weight and Glycemic Control
7. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
8. Cell Genesys Reports Additional Data From Phase 2 Clinical Trial of GVAX Immunotherapy for Pancreatic Cancer
9. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
10. New Study Results Provide Additional Data about Short- and Long-Term Use of Desvenlafaxine Succinate in the Treatment of Adults with Major Depressive Disorder
11. PTC Therapeutics Announces Additional Positive Interim Phase 2 Results of PTC124 in Duchenne Muscular Dystrophy
Post Your Comments:
(Date:8/21/2014)... -- CVS Caremark Corporation (NYSE: CVS ) announced ... payable in connection with its previously announced cash tender offers ... any and all of its 6.250% Senior Notes due 2027 ... maximum amount of its 6.125% Senior Notes due 2039, 5.750% ... (collectively, the "Maximum Tender Offer Notes" and together with the ...
(Date:8/21/2014)... , Aug. 21, 2014 /CNW/ - Bedrocan Cannabis ... three independent members to its Board of Directors, ... experience of the company, a leading licensed producer ... . Internationally, Bedrocan has 13 years, experience in ... in seven countries, including Canada. ...
(Date:8/21/2014)... 2014  SI-BONE, Inc. ( San Jose, California ... use of the iFuse Implant System, ® a ... the sacroiliac (SI) joint, announced that Priority Health ( ... Lumbar Fusion Medical Policy No. 91590-R4 providing positive coverage ... states that the fusion procedure, which employs the iFuse ...
Breaking Medicine Technology:CVS Caremark Corporation Announces Early Results of Tender Offers, Pricing, Election of Early Settlement and Increase in the Maximum Tender Offer Amount 2CVS Caremark Corporation Announces Early Results of Tender Offers, Pricing, Election of Early Settlement and Increase in the Maximum Tender Offer Amount 3CVS Caremark Corporation Announces Early Results of Tender Offers, Pricing, Election of Early Settlement and Increase in the Maximum Tender Offer Amount 4CVS Caremark Corporation Announces Early Results of Tender Offers, Pricing, Election of Early Settlement and Increase in the Maximum Tender Offer Amount 5CVS Caremark Corporation Announces Early Results of Tender Offers, Pricing, Election of Early Settlement and Increase in the Maximum Tender Offer Amount 6Senior Life Sciences Executives Join Bedrocan as Independent Directors 2Senior Life Sciences Executives Join Bedrocan as Independent Directors 3SI-BONE, Inc. Announces Positive Coverage Decision by Priority Health 2SI-BONE, Inc. Announces Positive Coverage Decision by Priority Health 3
... 29, 2011  Solos Endoscopy, Inc. (OTCPK: SNDY) is pleased ... in 2012 through the development and sales of its ... management of medical conditions. In 2011, Solos Endoscopy consummated ... in debt for the Company. The signed settlement agreement ...
... Today, Zacks Equity Research discusses the Pharma & Biotech, ... Human Genome Sciences Inc. (Nasdaq: HGSI ... and Perrigo Company (Nasdaq: PRGO ). ... synopsis of today,s Industry Outlook is presented below. The ...
Cached Medicine Technology:Solos Endoscopy, Inc. is Primed for Growth in 2012 2Solos Endoscopy, Inc. is Primed for Growth in 2012 3Zacks Industry Outlook Highlights: Vertex Pharma, Human Genome Sciences, Biogen Idec and Perrigo 2Zacks Industry Outlook Highlights: Vertex Pharma, Human Genome Sciences, Biogen Idec and Perrigo 3Zacks Industry Outlook Highlights: Vertex Pharma, Human Genome Sciences, Biogen Idec and Perrigo 4
(Date:8/22/2014)... August 22, 2014 Dealing with a drug ... when the addict is a child. Adolescent substance abuse has ... a long time. But a new helpline is now providing ... professional youth rehab for something like a teen drug ... designed to help make a positive impact in the community. ...
(Date:8/22/2014)... August 22, 2014 According to ... System and Adaptive Cruise Control (ACC) System Market ... Forecasts 2014 - 2019", published by MarketsandMarkets, classifies ... Market in terms of volume and value. The ... years as well as covers review of the ...
(Date:8/21/2014)... August 22, 2014 The natural loss of ... lines, wrinkles and sagging of skin. Using products to ... age 40, the body has lost about 15% of it ... 45%," says Kathy Heshelow, founder of Sublime Beauty®. "Collagen ... it - well, we know what happens." , Collagen in ...
(Date:8/21/2014)... (PRWEB) August 21, 2014 Local agencies ... have larger discounts for specific protection plans, according to ... helping consumers to quote life insurance from local agencies ... The local agents that appear inside of the national ... fast method of price reviews this year. Adults who ...
(Date:8/21/2014)... (PRWEB) August 21, 2014 AVEC ... to announce the addition of Kerry Gillespie as ... of healthcare management experience, Gillespie brings an extremely ... multiple executive management positions with prominent industry leading ... served as President of Triad Isotopes, Inc. a ...
Breaking Medicine News(10 mins):Health News:Cincinnati’s New Troubled Teen Helpline is Making a Difference in the Community 2Health News:Automotive Blind Spot Detection System Market Worth $2.8 Billion and Automotive Adaptive Cruise Control System Market Worth $6.1 Billion by 2019 – New Report 2Health News:Automotive Blind Spot Detection System Market Worth $2.8 Billion and Automotive Adaptive Cruise Control System Market Worth $6.1 Billion by 2019 – New Report 3Health News:Automotive Blind Spot Detection System Market Worth $2.8 Billion and Automotive Adaptive Cruise Control System Market Worth $6.1 Billion by 2019 – New Report 4Health News:4 Skincare Products That Boost and Nurture Collagen on Sale at Sublime Beauty® 2Health News:4 Skincare Products That Boost and Nurture Collagen on Sale at Sublime Beauty® 3Health News:Life Insurance from Local Agents Now Priced Nationally Through Complimentary Tool Online 2Health News:Kerry Gillespie Appointed as Chief Executive Officer of AVEC Health Solutions 2
... campuses of the University of California has found that flash-heating ... virus. ,The researchers hope that this technique - ... pan of water over a flame or single burner - ... nations will soon be able to more safely feed their ...
... rigorous U.S. trial comparing two traditional operations for stress ... urologists and urogynecologists supported by the National Institutes of ... more women achieve dryness than the Burch technique. ... a meticulous, relatively long-term comparison of these common surgeries ...
... given people another reason to quit smoking, by finding that ... depression in comparison to those who never smoke. ,The ... an elevated risk of depressive symptoms in short run, this ... long run. ,In other words, both completely ...
... Well, it doesnt have to be that way ... say that they have successfully managed to reduce ... containing vitamin A. ,Not only did the ... 23 people revealed it boosted levels of important skin ...
... a condition that most people prefer not to talk about, ... this embarrassing problem. It's called overactive bladder (OAB) and ... sometimes causing urine leakage. ,Now, to reduce the ... using nerve stimulation in the ankle to better help control ...
... chronic gum disease periodontitis, may have an increased risk of ... ,Periodontitis is an oral infection thought to be caused by ... well. ,The study was conducted by a team ... of New York at Buffalo and the Roswell Park Cancer ...
Cached Medicine News:Health News:Flash-heating Inactivates HIV in Breast Milk: Study 2Health News:Flash-heating Inactivates HIV in Breast Milk: Study 3Health News:Sling Surgery Better Than Burch for Treating Stress Incontinence in Women 2Health News:Sling Surgery Better Than Burch for Treating Stress Incontinence in Women 3Health News:Regular Smokers are at the Risk of Developing Depression 2Health News:Wrinkles can Be Really Ironed Out, Thanks to Vitamin A 2Health News:Stimulating the Ankle Can Help Patients With Overactive Bladder 2Health News:Men With Chronic Gum Disease at Higher Risk of Tongue Cancer 2
... take the words "mobile operating table" literally! The ... important functions of a general purpose operating table ... For table operations, a cable connected hand control, ... available. Plus, there is a control panel at ...
... carbon fiber c-arm table allows 50 ... brachytherapy, gynecology, gastroenterology, cardiovascular, orthopedic, ENT, ... design allows easy access for all ... 16-inch elevating travel, 16-inch longitudinal travel, ...
... for procedures where stability, access, and ... A cantilevered low attenuation carbon fiber ... The radiolucent area is free of ... and unobstructed C-Arm positioning. Functional design ...
... Lyphochek Elevated Immunosuppressant Control is a bilevel ... blood. This unique product is ideal for ... high Cyclosporine levels, such as C2 monitoring, ... at two hours post-dose., ,Lyphochek Elevated Immunosuppressant ...
Medicine Products: